Rhythm Pharmaceuticals, Inc. Stock News

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate it...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothal...

New registry study to focus on impact of fatigue in people with craniopharyngioma New registry study to focus on impact of fatigue in people with craniopharyngioma

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Meeker – Chairman, Chief Executive Officer and President Jennifer Lee – Executive Vice President, Head-North America Hunter Smith – Chief Financial Officer Yann Mazabraud – Executive Vice President, ...

-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 --  -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded lab...

Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expan...

BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 to report its fourth quarter and full year 2024 finan...

-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 --